Summary: UnitedHealth Group shares dropped roughly 3% on Monday following Berkshire Hathaway’s disclosure that it sold its stake in the healthcare conglomerate as part of a first-quarter portfolio reshuffle under CEO Greg Abel. Berkshire had earlier disclosed a purchase of 5 million UnitedHealth shares in August of last year. The stock’s pullback comes amid a wider context of operational improvements at UnitedHealth and strengthening quarterly results across major insurers.
UnitedHealth’s stock decline occurred after Berkshire said on Friday that it had exited its holding in the insurer. The August purchase of 5 million shares had previously helped lift the stock as investors welcomed signs of a potential turnaround under CEO Stephen Hemsley.
Bill Stone, chief investment officer at the Glenview Trust Company, noted that moves by Berkshire Hathaway tend to reverberate through related stocks whether Warren Buffett or others were behind the change. He added: "(UnitedHealth) has had a nice move this year, so perhaps this added to the temptation of profit taking since Berkshire exited." Glenview Trust holds Berkshire shares.
UnitedHealth is up about 20% year-to-date, having fallen more than 30% in the prior year, which made it the worst performer on the Dow Jones Industrial Average in 2025. Management changes and operational headwinds have shaped investor sentiment: Stephen Hemsley returned as CEO last year and has been working to rebuild confidence amid rising healthcare costs, criticism of insurance practices, the murder of a senior executive in late 2024, and a federal investigation into its government-backed plans.
James Harlow, senior vice president at Novare Capital Management, which owns 54,855 UnitedHealth shares, said the Berkshire exit "may take some air out of the stock near-term but does not diminish the operational turnaround that’s underway and seems to be headed in the right direction."
On the fundamentals front, UnitedHealth in April raised its full-year profit forecast and reported first-quarter earnings and revenue above Wall Street expectations. Other large insurers also delivered strong quarterly results and indicated improved control over elevated costs.
Morningstar analyst Julie Utterback commented on Berkshire’s sale, saying the move likely reflects roster changes more than any fundamental shift: "Berkshire’s move likely relates to roster changes more than anything else, adding the managed care story has been on an upswing during the first quarter earnings season." Her remarks framed the sale as part of broader portfolio adjustments rather than a direct verdict on UnitedHealth’s trajectory.
Key developments
- Berkshire Hathaway disclosed it has sold its UnitedHealth stake as part of first-quarter portfolio reshuffling under CEO Greg Abel.
- UnitedHealth shares fell about 3% on the disclosure; the stock is up roughly 20% year-to-date after a more than 30% drop last year.
- UnitedHealth raised its annual profit outlook in April and beat Wall Street estimates for first-quarter earnings and revenue; other major insurers reported stronger-than-expected quarterly results.
Sectors impacted
- Healthcare - insurers and managed care providers
- Financial markets - investor flows tied to large portfolio repositioning
Risks and uncertainties
- Short-term market reaction - Berkshire’s exit could prompt near-term profit taking, affecting UnitedHealth’s share price and related healthcare stocks.
- Operational and regulatory pressures - UnitedHealth continues to contend with rising healthcare costs, criticism of insurance practices, a federal probe into its government-backed plans, and reputational impact following the late-2024 murder of a senior executive.
- Portfolio management decisions - Berkshire’s roster adjustments under CEO Greg Abel introduce uncertainty about future headline-making trades that can influence investor sentiment across sectors.
The unfolding situation underscores how large institutional moves can influence market behavior even when company-level performance shows improvement. UnitedHealth’s upgraded profit outlook and its outperformance on quarterly metrics suggest operational momentum, but headline portfolio shifts and lingering regulatory and reputational issues remain factors for investors to monitor.